Literature DB >> 28918469

Aversive and non-aversive memory impairment in the mucopolysaccharidosis II mouse model.

Amanda Stapenhorst Azambuja1,2, Lilian Correa1,2, Bernardo Pappi Gabiatti2, Giselle Renata Martins2, Álvaro de Oliveira Franco2, Maria Flávia Marques Ribeiro1, Guilherme Baldo3,4.   

Abstract

Hunter syndrome (MPS II, OMIM 309900) is a lysosomal storage disorder due to deficient iduronate sulphatase activity. Patients present multiple cognitive alterations, and the aim of this work was to verify if MPS II mice also present some progressive cognitive alterations. For that, MPS II mice from 2 to 6 months of age were submitted to repeated open field and inhibitory avoidance tests to evaluate memory parameters. MPS II mice presented impaired memory at 6 months evaluated by open field test. They also performed poorly in the inhibitory avoidance test from 4 months. We conclude that MPS II mice develop cognitive alterations as the disease progresses. These tests can be used in the future to study the efficacy of therapeutic approaches in the central nervous system.

Entities:  

Keywords:  Hunter syndrome; Inhibitory avoidance; Mucopolysaccharidosis II; Repeated open field

Mesh:

Year:  2017        PMID: 28918469     DOI: 10.1007/s11011-017-0110-5

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  7 in total

1.  Mucopolysaccharidosis type II: identification of 30 novel mutations among Latin American patients.

Authors:  A C Brusius-Facchin; I V D Schwartz; C Zimmer; M G Ribeiro; A X Acosta; D Horovitz; I L Monlleó; M I B Fontes; A Fett-Conte; R P Oliveira Sobrinho; A R Duarte; R Boy; P Mabe; M Ascurra; M de Michelena; K L Tylee; G T N Besley; M C V Garreton; R Giugliani; S Leistner-Segal
Journal:  Mol Genet Metab       Date:  2013-09-01       Impact factor: 4.797

2.  Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II.

Authors:  Brianna Yund; Kyle Rudser; Alia Ahmed; Victor Kovac; Igor Nestrasil; Julian Raiman; Eva Mamak; Paul Harmatz; Robert Steiner; Heather Lau; Pooja Vekaria; Jeffrey R Wozniak; Kelvin O Lim; Kathleen Delaney; Chester Whitley; Elsa G Shapiro
Journal:  Mol Genet Metab       Date:  2014-12-09       Impact factor: 4.797

3.  Shotgun proteomics reveals possible mechanisms for cognitive impairment in Mucopolysaccharidosis I mice.

Authors:  Guilherme Baldo; Daniel Macedo Lorenzini; Diogenes Santiago Santos; Fabiana Quoos Mayer; Sandrine Vitry; Stephanie Bigou; Jean Michael Heard; Ursula Matte; Roberto Giugliani
Journal:  Mol Genet Metab       Date:  2014-12-13       Impact factor: 4.797

4.  The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome).

Authors:  A R Garcia; J Pan; J C Lamsa; J Muenzer
Journal:  J Inherit Metab Dis       Date:  2007-09-16       Impact factor: 4.982

5.  Progression of multiple behavioral deficits with various ages of onset in a murine model of Hurler syndrome.

Authors:  Dao Pan; Anthony Sciascia; Charles V Vorhees; Michael T Williams
Journal:  Brain Res       Date:  2007-10-23       Impact factor: 3.252

6.  Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice.

Authors:  Christian Hinderer; Nathan Katz; Jean-Pierre Louboutin; Peter Bell; Hongwei Yu; Mohamad Nayal; Karen Kozarsky; W Timothy O'Brien; Tamara Goode; James M Wilson
Journal:  Hum Gene Ther       Date:  2016-08-10       Impact factor: 5.695

7.  Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type II.

Authors:  Hélène F E Gleitz; Claire O'Leary; Rebecca J Holley; Brian W Bigger
Journal:  PLoS One       Date:  2017-02-16       Impact factor: 3.240

  7 in total
  1 in total

1.  Evidence for inflammasome activation in the brain of mucopolysaccharidosis type II mice.

Authors:  A S Azambuja; L N Pimentel-Vera; E A Gonzalez; E Poletto; C V Pinheiro; U Matte; R Giugliani; Guilherme Baldo
Journal:  Metab Brain Dis       Date:  2020-07-04       Impact factor: 3.584

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.